High therapy adherence but substantial limitations to daily activities amongst members of the Dutch inflammatory bowel disease patients' organization: A patient empowerment study

Alimentary Pharmacology and Therapeutics

Volumn 30, Issue 8, 2009, Pages 864-872

  Baars, J E ^a   Zelinkova, Z ^a   Mensink, P B F ^a   Markus, T ^b   Looman, C W N ^a   Kuipers, E J ^a   Van Der Woude, C J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Ulcerative Colitis   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MESALAZINE;

ADULT; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DAILY LIFE ACTIVITY; DISEASE DURATION; EMPOWERMENT; FEMALE; FUNCTIONAL STATUS; HEALTH CARE ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PATIENT COMPLIANCE; POPULATION RESEARCH; PRIORITY JOURNAL; QUESTIONNAIRE; SELF REPORT; ULCERATIVE COLITIS;

ACTIVITIES OF DAILY LIVING; ADRENAL CORTEX HORMONES; ADULT; AMINOSALICYLIC ACID; COLITIS, ULCERATIVE; CROHN DISEASE; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NETHERLANDS; PATIENT COMPLIANCE; PHYSICIAN-PATIENT RELATIONS;

EID: 70349208927     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04103.x     Document Type: Article

References (35)

1. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004 53 (Suppl 5 V1 16.
2. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005 353 : 487 497.
3. van Soest EM, Sturkenboom MC, Dieleman JP, et al. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther 2007 26 : 265 275.
4. Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001 96 : 2929 2933.
5. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006 23 : 577 585.
6. Hawthorne AB, Rubin G, Ghosh S. Review article: medication non-adherence in ulcerative colitis - strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther 2008 27 : 1157 1166.
7. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003 114 : 39 43.
8. Hanauer SB, Sninsky CA, Robinson M, et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group. Ann Intern Med 1996 124 : 204 211.
9. Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med 1991 115 : 350 355.
10. Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis 2005 11 : 421 427.
11. Nigro G, Angelini G, Grosso SB, et al. Psychiatric predictors of noncompliance in inflammatory bowel disease: psychiatry and compliance. J Clin Gastroenterol 2001 32 : 66 8.
12. Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003 98 : 1535 1544.
13. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003 18 : 191 198.
14. Bernal I, Domenech E, Garcia-Planella E, et al. Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Dig Dis Sci 2006 51 : 2165 2169.
15. Riley SA, Mani V, Goodman MJ, et al. Why do patients with ulcerative colitis relapse? Gut 1990 31 : 179 183. (Pubitemid 20092152)
16. Ediger JP, Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol 2007 102 : 1417 1426.
17. Cerveny P, Bortlik M, Kubena A, et al. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis 2007 13 : 1244 1249.
18. D'Inca R, Bertomoro P, Mazzocco K, et al. Risk factors for non-adherence to medication in inflammatory bowel disease patients. Aliment Pharmacol Ther 2008 27 : 166 172.
19. Lopez San RA, Bermejo F, Carrera E, et al. Adherence to treatment in inflammatory bowel disease. Rev Esp Enferm Dig 2005 97 : 249 257.
20. Meyer C, Muhlfeld A, Drexhage C, et al. Clinical research for patient empowerment - a qualitative approach on the improvement of heart health promotion in chronic illness. Med Sci Monit 2008 14 : CR358 65.
21. Aujoulat I, d'Hoore W, Deccache A. Patient empowerment in theory and practice: polysemy or cacophony? Patient Educ Couns 2007 66 : 13 20.
22. Gower JC, Hand DJ. Biplots, 22 edn. London : Chapman & Hall, 1996.
23. Nieuwboer A, De Weerdt W, Dom R, et al. A Frequency and correlation analysis of motor deficits in Parkinson patients. Disabil Rehabil 1998 4 : 142 150.
24. Bokemeyer B, Teml A, Roggel C, et al. Adherence to thiopurine treatment in out-patients with Crohn's disease. Aliment Pharmacol Ther 2007 26 : 217 225.
25. Choo PW, Rand CS, Inui TS, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999 37 : 846 857.
26. Haynes RB, Taylor DW, Sackett DL, et al. Can simple clinical measurements detect patient noncompliance? Hypertension 1980 2 : 757 764.
27. Langholz E, Munkholm P, Davidsen M, et al. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994 107 : 3 11.
28. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology 2006 130 : 650 656.
29. Longobardi T, Bernstein CN. Health care resource utilization in inflammatory bowel disease. Clin Gastroenterol Hepatol 2006 4 : 731 743.
30. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002 8 : 244 250.
31. Casellas F, Lopez-Vivancos J, Badia X, et al. Influence of inflammatory bowel disease on different dimensions of quality of life. Eur J Gastroenterol Hepatol 2001 13 : 567 572.
32. Canavan C, Abrams KR, Hawthorne B, et al. Long-term prognosis in Crohn's disease: factors that affect quality of life. Aliment Pharmacol Ther 2006 23 : 377 385.
33. Irvine EJ. Quality of life of patients with ulcerative colitis: past, present, and future. Inflamm Bowel Dis 2008 14 : 554 565.
34. Casellas F, Arenas JI, Baudet JS, et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis 2005 11 : 488 496.
35. Jones MP, Bratten J, Keefer L. Quality of life in patients with inflammatory bowel disease and irritable bowel syndrome differs between subjects recruited from clinic or the internet. Am J Gastroenterol 2007 102 : 2232 2237.